High-Dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: Results of the EORTC-GIMEMA AML-12 trial

Journal of Clinical Oncology

Volumn 32, Issue 3, 2014, Pages 219-228

  Willemze, Roelof ^a   Suciu, Stefan ^c   Meloni, Giovanna ⁱ   Labar, Boris ^y   Marie, Jean Pierre ^z   Halkes, Constantijn J M ^a   Muus, Petra ^b   Mistrik, Martin ^ac   Amadori, Sergio ^j   Specchia, Giorgina ^m   Fabbiano, Francesco ⁿ   Nobile, Francesco ^p   Sborgia, Marco ^q   Camera, Andrea ^r   Selleslag, Dominik L D ^e   Lefrer̀e Sr , Francois ^aa   Magro, Domenico ^s   Sica, Simona ^k   Cantore, Nicola ^t   Beksac, Meral ^ad   Berneman, Zwi ^f   Thomas, Xavier ^ab   Melillo, Lorella ^u   Guimaraes, Jose E ^ae   Leoni, Pietro ^v   Luppi, Mario ^w   Mitra, Maria E ^o   Bron, Dominique ^d   Fillet, Georges ^g   Marijt, Erik W A ^a   Venditti, Adriano ^j   Hagemeijer, Anne ^h   Mancini, Marco ⁱ   Jansen, Joop ^b   Cilloni, Daniela ^x   Meert, Liv ^c   Fazi, Paola ^l   Vignetti, Marco ^l   Trisolini, Silvia M ⁱ   Mandelli, Franco ⁱ   De Witte, Theo ^b   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c EORTC DATA CENTER   (Belgium)

^d ERASME HOSPITAL   (Belgium)

^e General Hospital St Jan   (Belgium)

^f ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^g UNIVERSITY OF LIÈGE   (Belgium)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^k FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^l Gruppo Italiano Malattie Ematologiche Dell' Adulto Foundation Central Office   (Italy)

^m UNIVERSITY OF BARI   (Italy)

ⁿ Laboratorio di Genetica Molecolare Ospedali Riuniti Villa Sofia V Cervello   (Italy)

^o UNIVERSITY OF PALERMO   (Italy)

^p BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^q Dipartimento di Medicina Trasfusionale   (Italy)

^r UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^s Pugliese Ciaccio Regional Hospital   (Italy)

^t S G MOSCATI HOSPITAL   (Italy)

^u CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^v Ospedale Regionale Torrette   (Italy)

^w UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^x UNIVERSITY OF TURIN   (Italy)

^y KBC Zagreb   (Croatia)

^z ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^aa HÔPITAL NECKER ENFANTS MALADES   (France)

^ab EDOUARD HERRIOT HOSPITAL   (France)

^ac UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^ad ANKARA UNIVERSITY   (Turkey)

^ae University of Porto   (Portugal)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; INTERLEUKIN 2; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVITIS; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GENE MUTATION; GROUPS BY AGE; HUMAN; INFECTIOUS COMPLICATION; INTENTION TO TREAT ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME; CONSOLIDATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; EUROPE; GENETICS; INDUCTION CHEMOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; MUTATION; RISK FACTOR;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONSOLIDATION CHEMOTHERAPY; CYTARABINE; DAUNORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; EUROPE; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84897018280     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.8571     Document Type: Article

References (20)

1. Burnett A, Wetzler M, Löwenberg B: Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29:487-494, 2011
2. Mandelli F, Vignetti M, Suciu S, et al: Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: The EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 27:5397-5403, 2009
3. Rudnick SA, Cadman EC, Capizzi RL, et al: High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 44:1189-1193, 1979
4. Willemze R, Zwaan FE, Keuning JJ, et al: Treatment of refractory acute leukaemia with high dose cytosine arabinoside. Br J Haematol 51:497-498, 1982
5. Herzig RH, Lazarus HM, Wolff SN, et al: High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 3:992-997, 1985 (Pubitemid 15028571)
6. Wolff SN, Marion J, Stein RS, et al: High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: A pilot study. Blood 65:1407-1411, 1985 (Pubitemid 15057947)
7. Phillips GL, Reece DE, Shepherd JD, et al: High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 77:1429-1435, 1991
8. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med 331:896-903, 1994 (Pubitemid 24299870)
9. Bradstock KF, Matthews JP, Lowenthal RM, et al: A randomized trial of high- versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 105:481-488, 2005 (Pubitemid 40070725)
10. 2 within first consolidation in acute myeloid leukemia: Results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol 29:2696-2702, 2011
11. Miyawaki S, Ohtake S, Fujisawa S, et al: A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: The JALSG AML201 study. Blood 117:2366-2372, 2011
12. Farag SS, Ruppert AS, Mrózek K, et al: Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study. J Clin Oncol 23:482-493, 2005 (Pubitemid 46224225)
13. Lówenberg B: Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 121:26-28, 2013
14. Bishop JF, Matthews JP, Young GA, et al: A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87:1710-1717, 1996 (Pubitemid 26068888)
15. Weick JK, Kopecky KJ, Appelbaum FR, et al: A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study. Blood 88:2841-2851, 1996 (Pubitemid 26357364)
16. Büchner T, Berdel WE, Schoch C, et al: Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 24:2480-2489, 2006 (Pubitemid 46655599)
17. Löwenberg B, Pabst T, Vellenga E, et al: Cytarabine dose for acute myeloid leukemia. N Engl J Med 364:1027-1036, 2011
18. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990 (Pubitemid 20148273)
19. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data (ed 2). Hoboken, NJ, John Wiley & Sons, 2002
20. Suciu S, Mandelli F, de Witte T, et al: Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 102:1232-1240, 2003 (Pubitemid 36988027)